Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 175

1.

Thrombocytosis and leukocytosis interaction in vascular complications of essential thrombocythemia.

Carobbio A, Finazzi G, Antonioli E, Guglielmelli P, Vannucchi AM, Delaini F, Guerini V, Ruggeri M, Rodeghiero F, Rambaldi A, Barbui T.

Blood. 2008 Oct 15;112(8):3135-7. doi: 10.1182/blood-2008-04-153783. Epub 2008 Jun 27.

2.

Leukocytosis and risk stratification assessment in essential thrombocythemia.

Carobbio A, Antonioli E, Guglielmelli P, Vannucchi AM, Delaini F, Guerini V, Finazzi G, Rambaldi A, Barbui T.

J Clin Oncol. 2008 Jun 1;26(16):2732-6. doi: 10.1200/JCO.2007.15.3569. Epub 2008 Apr 28.

PMID:
18443353
3.

Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors, and Jak2 mutation status.

Carobbio A, Finazzi G, Guerini V, Spinelli O, Delaini F, Marchioli R, Borrelli G, Rambaldi A, Barbui T.

Blood. 2007 Mar 15;109(6):2310-3. Epub 2006 Nov 16.

4.

Is the absence of JAK2 mutation a risk factor for bleeding in essential thrombocythemia? An analysis of 106 patients.

Patriarca A, Pompetti F, Malizia R, Iuliani O, Di Marzio I, Spadano A, Dragani A.

Blood Transfus. 2010 Jan;8(1):21-7. doi: 10.2450/2009.0004-09.

5.

The association of JAK2V617F mutation and leukocytosis with thrombotic events in essential thrombocythemia.

Hsiao HH, Yang MY, Liu YC, Lee CP, Yang WC, Liu TC, Chang CS, Lin SF.

Exp Hematol. 2007 Nov;35(11):1704-7. Epub 2007 Oct 17.

PMID:
17920754
6.
7.

Leukocytosis at diagnosis and the risk of subsequent thrombosis in patients with low-risk essential thrombocythemia and polycythemia vera.

Gangat N, Wolanskyj AP, Schwager SM, Hanson CA, Tefferi A.

Cancer. 2009 Dec 15;115(24):5740-5. doi: 10.1002/cncr.24664.

8.

Platelet count in essential thrombocythemia: the more the better?

Tefferi A.

Blood. 2008 Oct 15;112(8):3526; author reply 3526-7. doi: 10.1182/blood-2008-07-168807. No abstract available.

9.

Impact of leukocytosis on thrombotic risk and survival in 532 patients with essential thrombocythemia: a retrospective study.

Palandri F, Polverelli N, Catani L, Ottaviani E, Baccarani M, Vianelli N.

Ann Hematol. 2011 Aug;90(8):933-8. doi: 10.1007/s00277-010-1154-3. Epub 2011 Feb 2.

PMID:
21287350
10.

Perspectives on thrombosis in essential thrombocythemia and polycythemia vera: is leukocytosis a causative factor?

Barbui T, Carobbio A, Rambaldi A, Finazzi G.

Blood. 2009 Jul 23;114(4):759-63. doi: 10.1182/blood-2009-02-206797. Epub 2009 Apr 16.

11.

Leukocytosis is a risk factor for recurrent arterial thrombosis in young patients with polycythemia vera and essential thrombocythemia.

De Stefano V, Za T, Rossi E, Vannucchi AM, Ruggeri M, Elli E, Micò C, Tieghi A, Cacciola RR, Santoro C, Gerli G, Guglielmelli P, Pieri L, Scognamiglio F, Rodeghiero F, Pogliani EM, Finazzi G, Gugliotta L, Leone G, Barbui T; GIMEMA Chronic Myeloproliferative Neoplasms Working Party.

Am J Hematol. 2010 Feb;85(2):97-100. doi: 10.1002/ajh.21593.

12.

Management of extreme thrombocytosis in otherwise low-risk essential thrombocythemia; does number matter?

Tefferi A, Gangat N, Wolanskyj AP.

Blood. 2006 Oct 1;108(7):2493-4. No abstract available.

13.

[Vascular complications of essential thrombocythemia].

Bellucci S.

Bull Acad Natl Med. 2007 Mar;191(3):519-30; discussion 530-3. Review. French.

PMID:
18072651
14.

Sex and age as prognostic factors in essential thrombocythemia.

Randi ML, Fabris F, Rossi C, Tison T, Barbone E, Girolami A.

Haematologica. 1992 Sep-Oct;77(5):402-4.

PMID:
1483589
15.

Observation versus antiplatelet therapy as primary prophylaxis for thrombosis in low-risk essential thrombocythemia.

Alvarez-Larrán A, Cervantes F, Pereira A, Arellano-Rodrigo E, Pérez-Andreu V, Hernández-Boluda JC, Ayats R, Salvador C, Muntañola A, Bellosillo B, Vicente V, Hernández-Nieto L, Burgaleta C, Xicoy B, Besses C.

Blood. 2010 Aug 26;116(8):1205-10; quiz 1387. doi: 10.1182/blood-2010-01-263319. Epub 2010 May 27.

16.

The role of the Platelet Function Analyzer (PFA)-100 and platelet aggregometry in the differentiation of essential thrombocythemia from reactive thrombocytosis.

Tsantes AE, Dimoula A, Bonovas S, Mantzios G, Tsirigotis P, Zoi K, Kalamara E, Kardoulaki A, Sitaras N, Travlou A, Dervenoulas J, Vaiopoulos G.

Thromb Res. 2010 Feb;125(2):142-6. doi: 10.1016/j.thromres.2009.06.030. Epub 2009 Aug 7.

PMID:
19664802
17.

Essential thrombocythemia: a hypercoagulable state.

Hunter Mellado RF, Oppenheimer Catalá J, Vázquez Medina J.

Bol Asoc Med P R. 1991 Oct;83(10):436-9.

PMID:
1789889
18.

Clinical features and course of refractory anemia with ring sideroblasts associated with marked thrombocytosis.

Broseus J, Florensa L, Zipperer E, Schnittger S, Malcovati L, Richebourg S, Lippert E, Cermak J, Evans J, Mounier M, Raya JM, Bailly F, Gattermann N, Haferlach T, Garand R, Allou K, Besses C, Germing U, Haferlach C, Travaglino E, Luno E, Pinan MA, Arenillas L, Rozman M, Perez Sirvent ML, Favre B, Guy J, Alonso E, Ahwij N, Jerez A, Hermouet S, Maynadié M, Cazzola M, Girodon F.

Haematologica. 2012 Jul;97(7):1036-41. doi: 10.3324/haematol.2011.053918. Epub 2012 Apr 24.

19.

Increased risk of recurrent thrombosis in patients with essential thrombocythemia carrying the homozygous JAK2 V617F mutation.

De Stefano V, Za T, Rossi E, Vannucchi AM, Ruggeri M, Elli E, Micò C, Tieghi A, Cacciola RR, Santoro C, Vianelli N, Guglielmelli P, Pieri L, Scognamiglio F, Cacciola E, Rodeghiero F, Pogliani EM, Finazzi G, Gugliotta L, Leone G, Barbui T; GIMEMA Chronic Myeloproliferative Neoplasms Working Party.

Ann Hematol. 2010 Feb;89(2):141-6. doi: 10.1007/s00277-009-0788-5. Epub 2009 Jul 7.

PMID:
19582452
20.

Analysis of risk factors predicting thrombotic and/or haemorrhagic complications in 306 patients with essential thrombocythemia.

Radaelli F, Colombi M, Calori R, Zilioli VR, Bramanti S, Iurlo A, Zanella A.

Hematol Oncol. 2007 Sep;25(3):115-20.

PMID:
17464935

Supplemental Content

Support Center